Drug Search Results

Ficlatuzumab

Alternative Names: ficlatuzumab, av-299, av299, av 299
Latest Update: 2024-06-17
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: C-Met Antagonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: Fast Track - Head and Neck Cancer|Squamous Cell Carcinoma *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AVEO
Company Location: BOSTON MA 02108
Company CEO: Michael Bailey
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ficlatuzumab

Countries in Clinic: Australia, Belgium, Bulgaria, Czech Republic, France, Germany, Hungary, Italy, Netherlands, Poland, Romania, Spain, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Head and Neck Cancer|Squamous Cell Carcinoma

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
FIERCE-HN	P3	Recruiting	Squamous Cell Carcinoma\|Head and Neck Cancer	2027-08-01
AV-299-23-301	P3	Not yet recruiting	Squamous Cell Carcinoma\|Head and Neck Cancer	2027-04-29

Recent News Events

Date	Type	Title
05/09/2024	News Article	XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
01/16/2024	News Article	AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
08/01/2023	PubMed	Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.
06/01/2023	PubMed	Computational Drug Discovery in Ankylosing Spondylitis-Induced Osteoporosis Based on Data Mining and Bioinformatics Analysis.
05/08/2023	PubMed	Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer.
06/22/2022	News Article	AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
01/04/2022	News Article	AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic HNSCC

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions